Related Experiment Video
Updated: Apr 7, 2026

Mapping Bacterial Functional Networks and Pathways in Escherichia Coli using Synthetic Genetic Arrays
Published on: November 12, 2012
Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in Escherichia coli
Madison E Stellfox1, Yohei Doi1,2
1Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Abstract:
This challenging clinical case highlights the impact of PBP3 insertions in Escherichia coli, which reduce susceptibility to key β-lactam agents and complicate treatment, particularly in the setting of NDM production (C. Fabrizio, F. Valzano, S. Giuliano, E. Morelli, et al., Antimicrob Agents Chemother 70:e00887-25, 2026, https://doi.org/10.1128/aac.00887-25). Clinical improvement was achieved with imipenem-relebactam plus aztreonam, supporting the idea that targeting multiple penicillin-binding proteins can overcome functional redundancy. These findings emphasize the clinical relevance of PBP3-mediated resistance and the need for treatment strategies that address complex β-lactam resistance in Gram-negative pathogens.
Insights
Penicillin-binding protein 3 (PBP3) insertions in Escherichia coli reduce susceptibility to beta-lactam antibiotics, complicating treatment. Combination therapy with imipenem-relebactam and aztreonam successfully treated a patient with NDM-producing E. coli.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Penicillin-binding protein 3 (PBP3) insertions in Escherichia coli can confer resistance to beta-lactam antibiotics.
- This resistance mechanism complicates treatment, especially when co-occurring with New Delhi metallo-beta-lactamase (NDM) production.
Purpose of the Study:
- To highlight the clinical impact of PBP3 insertions in Escherichia coli.
- To present a successful treatment strategy for a complex case of beta-lactam resistant E. coli.
Main Methods:
- Case report of a patient with NDM-producing Escherichia coli.
- Clinical assessment of treatment response to imipenem-relebactam plus aztreonam.
Main Results:
- PBP3 insertions significantly reduced susceptibility to key beta-lactam agents.
- Clinical improvement was achieved with the combination therapy of imipenem-relebactam and aztreonam.
- Targeting multiple penicillin-binding proteins can overcome functional redundancy in resistance.
Conclusions:
- PBP3-mediated resistance is clinically relevant in Gram-negative pathogens.
- Novel treatment strategies are needed to address complex beta-lactam resistance.
- Combination therapy targeting multiple penicillin-binding proteins shows promise for treating resistant infections.
Related Concept Videos
Bacterial Gastroenteritis
Stringent Response in E. coli
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

